GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
Procedures for obtaining preparatory documents for the General Meeting are described below. PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 19, … [Read more…]
